BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FB-101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FB-101\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07126704-1562@assetmemo.bio
DTSTAMP:20261121T005314Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:FB-101: Phase 1 readout est. (NCT07126704)
DESCRIPTION:FB-101\, phase 1.\nStudy: A Phase 1\, SAD and MAD to Evaluate t
 he Safety\, Tolerability\, Pharmacokinetics\, and Pharmacodynamics of Oral
  FB-101 in Healthy Adult Male Subjects\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fb-101#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712670
 4
URL:https://assetmemo.bio/drug/fb-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
